Acumen Pharmaceuticals Stock Beta
| ABOS Stock | USD 3.40 0.04 1.19% |
Acumen Pharmaceuticals fundamentals help investors to digest information that contributes to Acumen Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Acumen Stock. The fundamental analysis module provides a way to measure Acumen Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acumen Pharmaceuticals stock.
Acumen | Beta |
Acumen Pharmaceuticals Company Beta Analysis
Acumen Pharmaceuticals' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Acumen Pharmaceuticals Beta | 0.082 |
Most of Acumen Pharmaceuticals' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acumen Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Acumen Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Acumen Pharmaceuticals is extremely important. It helps to project a fair market value of Acumen Stock properly, considering its historical fundamentals such as Beta. Since Acumen Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Acumen Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Acumen Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Acumen Pharmaceuticals has a Beta of 0.082. This is 90.47% lower than that of the Biotechnology sector and 94.1% lower than that of the Health Care industry. The beta for all United States stocks is 154.67% lower than that of the firm.
Acumen Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acumen Pharmaceuticals' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acumen Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acumen Pharmaceuticals by comparing valuation metrics of similar companies.Acumen Pharmaceuticals is currently under evaluation in beta category among related companies.
Acumen Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Acumen Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Acumen Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Acumen Pharmaceuticals' value.| Shares | Pathstone Holdings Llc | 2023-12-31 | 479.1 K | Ikarian Capital, Llc | 2023-12-31 | 315.3 K | Geode Capital Management, Llc | 2023-12-31 | 264.6 K | Blackrock Inc | 2023-12-31 | 248.1 K | Two Sigma Investments Llc | 2023-12-31 | 244.4 K | Goldman Sachs Group Inc | 2023-12-31 | 229.5 K | Citigroup Inc | 2023-12-31 | 147.8 K | Man Group Plc | 2023-12-31 | 144.6 K | Two Sigma Advisers, Llc | 2023-12-31 | 129.7 K | Ra Capital Management, Llc | 2023-12-31 | 14.9 M | Sands Capital Ventures, Llc | 2023-12-31 | 3.4 M |
As returns on the market increase, Acumen Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Acumen Pharmaceuticals is expected to be smaller as well.
Acumen Fundamentals
| Return On Equity | -0.23 | ||||
| Return On Asset | -0.15 | ||||
| Current Valuation | (10.61 M) | ||||
| Shares Outstanding | 60.08 M | ||||
| Shares Owned By Insiders | 9.12 % | ||||
| Shares Owned By Institutions | 72.47 % | ||||
| Number Of Shares Shorted | 1.05 M | ||||
| Price To Book | 0.84 X | ||||
| Price To Sales | 538.78 X | ||||
| Gross Profit | (32.36 M) | ||||
| EBITDA | (60.95 M) | ||||
| Net Income | (52.37 M) | ||||
| Cash And Equivalents | 189.91 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 31.05 M | ||||
| Current Ratio | 37.21 X | ||||
| Book Value Per Share | 4.61 X | ||||
| Cash Flow From Operations | (43.06 M) | ||||
| Short Ratio | 3.29 X | ||||
| Earnings Per Share | (1.08) X | ||||
| Price To Earnings To Growth | (0.23) X | ||||
| Target Price | 12.8 | ||||
| Number Of Employees | 51 | ||||
| Beta | 0.082 | ||||
| Market Capitalization | 201.87 M | ||||
| Total Asset | 310.12 M | ||||
| Retained Earnings | (222.8 M) | ||||
| Working Capital | 233.64 M | ||||
| Net Asset | 310.12 M |
About Acumen Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acumen Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acumen Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acumen Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Acumen Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Acumen Pharmaceuticals' short interest history, or implied volatility extrapolated from Acumen Pharmaceuticals options trading.
Pair Trading with Acumen Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acumen Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acumen Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Acumen Stock
| 0.89 | VTYX | Ventyx Biosciences | PairCorr |
Moving against Acumen Stock
| 0.51 | ZURA | Zura Bio Limited Financial Report 10th of May 2024 | PairCorr |
| 0.45 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
The ability to find closely correlated positions to Acumen Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Acumen Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Acumen Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Acumen Pharmaceuticals to buy it.
The correlation of Acumen Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Acumen Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Acumen Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Acumen Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Acumen Pharmaceuticals Piotroski F Score and Acumen Pharmaceuticals Altman Z Score analysis. For more information on how to buy Acumen Stock please use our How to Invest in Acumen Pharmaceuticals guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Complementary Tools for Acumen Stock analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |
Is Acumen Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Acumen Pharmaceuticals. If investors know Acumen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Acumen Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Revenue Per Share 0.033 | Return On Assets (0.15) | Return On Equity (0.23) |
The market value of Acumen Pharmaceuticals is measured differently than its book value, which is the value of Acumen that is recorded on the company's balance sheet. Investors also form their own opinion of Acumen Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Acumen Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acumen Pharmaceuticals' market value can be influenced by many factors that don't directly affect Acumen Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acumen Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Acumen Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acumen Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.